
Cingulate Inc. Share Price
CING
$3.92
-$0.30 (-7.1%) Last updated on 29 Aug, 2025 | 01:21 ISTCingulate Inc. Stock Performance
Open $4.09 | Prev. Close $4.22 | Circuit Range N/A |
Day Range $3.91 - $4.09 | Year Range $3.03 - $10.09 | Volume 2,067 |
Average Traded $4.01 |
Cingulate Inc. Share Price Chart
$3.92
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc. Historical Data
Day | Open | Close | Change % |
---|---|---|---|
28-Aug-25 | $4.09 | $3.91 | -7.46% |
27-Aug-25 | $4.37 | $4.22 | -1.74% |
26-Aug-25 | $4.38 | $4.30 | +2.87% |
25-Aug-25 | $4.23 | $4.18 | +0.00% |
22-Aug-25 | $3.98 | $4.18 | +3.72% |
21-Aug-25 | $4.01 | $4.03 | +4.13% |
20-Aug-25 | $3.75 | $3.87 | +2.65% |